Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation.

ABSTRACT:

Purpose

Diastolic dysfunction is an increasingly common cardiac pathology linked to heart failure with preserved ejection fraction. Previous studies have implicated glucagon-like peptide 1 (GLP-1) receptor agonists as potential therapies for improving diastolic dysfunction. In this study, we investigate the physiologic and metabolic changes in a mouse model of angiotensin II (AngII)-mediated diastolic dysfunction with and without the GLP-1 receptor agonist liraglutide (Lira).

Methods

Mice were divided into sham, AngII, or AngII+Lira therapy for 4 weeks. Mice were monitored for cardiac function, weight change, and blood pressure at baseline and after 4 weeks of treatment. After 4 weeks of treatment, tissue was collected for histology, protein analysis, targeted metabolomics,

SUBMITTER: Rutledge C 

PROVIDER: S-EPMC10788853 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature